Review of Related Factors for Persistent Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma

Nevin Varghese,Amry Majeed,Suraj Nyalakonda,Tina Boortalary,Dina Halegoua-DeMarzio,Hie-Won Hann
DOI: https://doi.org/10.3390/cancers16040777
2024-02-15
Cancers
Abstract:Chronic hepatitis B virus (HBV) infection is the largest global cause of hepatocellular carcinoma (HCC). Current HBV treatment options include pegylated interferon-alpha and nucleos(t)ide analogues (NAs), which have been shown to be effective in reducing HBV DNA levels to become undetectable. However, the literature has shown that some patients have persistent risk of developing HCC. The mechanism in which this occurs has not been fully elucidated. However, it has been discovered that HBV's covalently closed circular DNA (cccDNA) integrates into the critical HCC driver genes in hepatocytes upon initial infection; additionally, these are not targets of current NA therapies. Some studies suggest that HBV undergoes compartmentalization in peripheral blood mononuclear cells that serve as a sanctuary for replication during antiviral therapy. The aim of this review is to expand on how patients with HBV may develop HCC despite years of HBV viral suppression and carry worse prognosis than treatment-naive HBV patients who develop HCC. Furthermore, HCC recurrence after initial surgical or locoregional treatment in this setting may cause carcinogenic cells to behave more aggressively during treatment. Curative novel therapies which target the life cycle of HBV, modulate host immune response, and inhibit HBV RNA translation are being investigated.
oncology
What problem does this paper attempt to address?
The problem this paper attempts to address is: Despite effective antiviral treatment, patients with chronic hepatitis B (HBV) still have a persistent risk of hepatocellular carcinoma (HCC). Specifically, the paper explores the factors, pathophysiological mechanisms, and existing evidence related to this persistent risk, aiming to provide a foundation for further screening and the eventual development of a cure. ### Background of the Paper - **Global Impact**: HBV infection is the largest cause of hepatocellular carcinoma (HCC) worldwide, affecting approximately 300 million people. - **Current Treatment Status**: Current treatment options include pegylated interferon-α and nucleos(t)ide analogs (NAs), which can significantly reduce HBV DNA levels to undetectable levels. - **Persistent Risk**: Despite effective suppression of viral load and even the disappearance of surface antigens, some patients still have a risk of developing HCC. ### Research Objectives - **Review Related Factors**: The paper aims to review the factors related to the persistent risk of HBV-associated HCC, including pathophysiological mechanisms and existing evidence. - **Explain Mechanisms**: Explore why patients still have a risk of HCC even when viral load is effectively controlled. - **Provide Basis**: Provide a scientific basis for appropriate screening strategies and the eventual development of a cure. ### Main Findings - **cccDNA Integration**: The covalently closed circular DNA (cccDNA) of HBV integrates into key genes of hepatocytes during initial infection, which may be one of the reasons for malignant transformation. - **Immune Evasion**: HBV can evade the host's immune response through various mechanisms, leading to chronic infection. - **Other Mechanisms**: Including the progression of cirrhosis, inflammatory responses caused by HBV infection, and the carcinogenic effects of HBV genome integration into hepatocyte chromosomes. ### Conclusion - **Persistent Risk**: Even with effective suppression of viral load, patients with HBV infection still have a risk of developing HCC. - **Future Directions**: Further research is needed to clarify the relationship and factors associated with HBV-related HCC risk to develop more effective screening and treatment strategies. Through these studies, the paper provides important insights into the complex mechanisms of HBV-related HCC and points the way for future clinical practice and research.